Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Johnson and Johnson
Medtronic
Julphar
Novartis
Chinese Patent Office
Cipla
AstraZeneca
Express Scripts
UBS

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,808,146

« Back to Dashboard

Which drugs does patent 5,808,146 protect, and when does it expire?

Patent 5,808,146 protects AXUMIN and is included in one NDA.

This patent has ten patent family members in five countries.
Summary for Patent: 5,808,146
Title: Amino acid analogs for tumor imaging
Abstract:The invention provides novel amino acid compounds of use in detecting and evaluating brain and body tumors. These compounds combine the advantageous properties of 1-amino-cycloalkyl-1-carboxylic acids, namely, their rapid uptake and prolonged retention in tumors with the properties of halogen substituents, including certain useful halogen isotopes including fluorine-18, iodine-123, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77 and bromine-82. In one aspect, the invention features amino acid compounds that have a high specificity for target sites when administered to a subject in vivo. Preferred amino acid compounds show a target to non-target ratio of at least 5:1, are stable in vivo and substantially localized to target within 1 hour after administration. An especially preferred amino acid compound is [.sup.18 F]-1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC). In another aspect, the invention features pharmaceutical compositions comprised of an .alpha.-amino acid moiety attached to either a four, five, or a six member carbon-chain ring. In addition, the invention features analogs of .alpha.-aminoisobutyric acid.
Inventor(s): Goodman; Mark M. (Atlanta, GA), Shoup; Timothy (Decatur, GA)
Assignee: Emory University (Atlanta, GA)
Application Number:08/554,906
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 5,808,146

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Blue Earth AXUMIN fluciclovine f-18 SOLUTION;INTRAVENOUS 208054-001 May 27, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,808,146

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,817,776 Amino acid analogs for tumor imaging ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,808,146

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 1120497 ➤ Sign Up
Australia 720738 ➤ Sign Up
Canada 2237218 ➤ Sign Up
European Patent Office 0862464 ➤ Sign Up
Japan 2000500442 ➤ Sign Up
Japan 3992736 ➤ Sign Up
Japan 2011207901 ➤ Sign Up
Japan 5341136 ➤ Sign Up
Japan 2007246535 ➤ Sign Up
World Intellectual Property Organization (WIPO) 9717092 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Cipla
Queensland Health
US Department of Justice
Harvard Business School
Chinese Patent Office
McKinsey
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot